Ambu (CPSE:AMBU B) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

AMBU B Overzicht aandelen

Ambu A/S ontwikkelt, produceert en verkoopt medische hulpmiddelen aan ziekenhuizen, klinieken en hulpdiensten over de hele wereld.

Over het bedrijf

AMBU B fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	4/6
Prestaties in het verleden	2/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De winst zal naar verwachting met 21.23% per jaar groeien

Dit jaar winstgevend geworden

Risicoanalyse

Volatiele aandelenkoers in de afgelopen 3 maanden

Ambu A/S Concurrenten

Demant

CPSE:DEMANT

DKK 58.6b

Embla Medical hf

CPSE:EMBLA

DKK 14.4b

Coloplast

CPSE:COLO B

DKK 201.5b

Jiangsu Yuyue Medical Equipment & Supply

SZSE:002223

CN¥34.8b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Ambu
Historische aandelenkoersen
Huidige aandelenkoers	DKK 129.35
52 Week Hoogtepunt	DKK 154.60
52 Week Laag	DKK 65.62
Bèta	0.77
11 maand verandering	-4.68%
3 maanden verandering	-3.43%
1 Jaar Verandering	89.05%
33 jaar verandering	-30.48%
5 jaar verandering	20.33%
Verandering sinds IPO	7,453.29%

Recent nieuws en updates

Ambu A/S Just Beat EPS By 15%: Here's What Analysts Think Will Happen Next

Sep 02

Here's What's Concerning About Ambu's (CPH:AMBU B) Returns On Capital

Aug 06

Recent updates

Results: Ambu A/S Exceeded Expectations And The Consensus Has Updated Its Estimates

Feb 01

A Piece Of The Puzzle Missing From Ambu A/S' (CPH:AMBU B) Share Price

Jan 02

Is Ambu A/S (CPH:AMBU B) Trading At A 42% Discount?

Oct 31

Ambu (CPH:AMBU B) Will Want To Turn Around Its Return Trends

Sep 22

Does Ambu (CPH:AMBU B) Have A Healthy Balance Sheet?

Aug 19

Does This Valuation Of Ambu A/S (CPH:AMBU B) Imply Investors Are Overpaying?

Jul 12

Returns On Capital At Ambu (CPH:AMBU B) Paint A Concerning Picture

Jun 22

Ambu (CPH:AMBU B) Has A Somewhat Strained Balance Sheet

May 07

Returns On Capital At Ambu (CPH:AMBU B) Paint A Concerning Picture

Mar 24

We Think Ambu (CPH:AMBU B) Is Taking Some Risk With Its Debt

Jan 20

Ambu (CPH:AMBU B) Will Be Hoping To Turn Its Returns On Capital Around

Dec 08

Is Ambu A/S (CPH:AMBU B) Trading At A 30% Discount?

Sep 23

Ambu (CPH:AMBU B) Will Want To Turn Around Its Return Trends

Sep 08

We Think Ambu (CPH:AMBU B) Is Taking Some Risk With Its Debt

Aug 21

Ambu (CPH:AMBU B) Could Be Struggling To Allocate Capital

Jun 06

These 4 Measures Indicate That Ambu (CPH:AMBU B) Is Using Debt Extensively

May 19

Does Ambu (CPH:AMBU B) Have A Healthy Balance Sheet?

Jan 23

Are Investors Undervaluing Ambu A/S (CPH:AMBU B) By 27%?

Dec 12

Does Ambu (CPH:AMBU B) Have A Healthy Balance Sheet?

Oct 04

Rendement voor aandeelhouders

	AMBU B	DK Medical Equipment	DK Markt
7D	2.8%	1.9%	-0.9%
1Y	89.1%	22.8%	19.7%

Rendement versus industrie: AMBU B overtrof de Danish Medical Equipment industrie, die het afgelopen jaar een rendement 17.6 % opleverde.

Rendement versus markt: AMBU B overtrof de Danish markt, die het afgelopen jaar een rendement opleverde van 21.8 %.

Prijsvolatiliteit

Is AMBU B's price volatile compared to industry and market?
AMBU B volatility
AMBU B Average Weekly Movement	6.2%
Medical Equipment Industry Average Movement	5.6%
Market Average Movement	4.2%
10% most volatile stocks in DK Market	8.9%
10% least volatile stocks in DK Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van AMBU B is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van AMBU B is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen Danish.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1937	4,900	Britt Jensen	www.ambu.com

Ambu A/S ontwikkelt, produceert en verkoopt medische apparatuur aan ziekenhuizen, klinieken en hulpdiensten wereldwijd. Het bedrijf biedt producten voor anesthesie, patiëntbewaking en diagnostiek. Het bedrijf biedt ook endoscopie producten, zoals bronchoscopen, rhinolaryngoscopen, duodenoscopen, cystoscopen, en weergave-units; en neurologie producten, waaronder EEG en EMG elektroden, EMG geleide injecties, en intraoperatieve monitoring producten.

Ambu A/S Samenvatting

Hoe verhouden de winst en inkomsten van Ambu zich tot de beurswaarde?
AMBU B fundamentele statistieken
Marktkapitalisatie	DKK 34.46b
Inkomsten(TTM)	DKK 450.00m
Inkomsten(TTM)	DKK 5.26b

76.6x

Koers/Winstverhouding

6.5x

P/S-verhouding

Is AMBU B overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
AMBU B resultatenrekening (TTM)
Inkomsten	DKK 5.26b
Kosten van inkomsten	DKK 2.16b
Brutowinst	DKK 3.10b
Overige uitgaven	DKK 2.65b
Inkomsten	DKK 450.00m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 05, 2024

Winst per aandeel (EPS)	1.69
Brutomarge	58.88%
Nettowinstmarge	8.55%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde AMBU B op de lange termijn?

Bekijk historische prestaties en vergelijking

AMBU B Overzicht aandelen

Beloningen

Risicoanalyse

Ambu A/S Concurrenten

CPSE:DEMANT

DKK 58.6b

CPSE:EMBLA

DKK 14.4b

CPSE:COLO B

DKK 201.5b

SZSE:002223

CN¥34.8b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Ambu A/S, Annual General Meeting, Dec 03, 2025

Ambu A/S to Report Q1, 2025 Results on Jan 30, 2025

Ambu A/S Just Beat EPS By 15%: Here's What Analysts Think Will Happen Next

Third quarter 2024 earnings: EPS exceeds analyst expectations

Price target increased by 8.1% to kr.123

Here's What's Concerning About Ambu's (CPH:AMBU B) Returns On Capital

Recent updates

Ambu A/S, Annual General Meeting, Dec 03, 2025

Ambu A/S to Report Q1, 2025 Results on Jan 30, 2025

Ambu A/S Just Beat EPS By 15%: Here's What Analysts Think Will Happen Next

Third quarter 2024 earnings: EPS exceeds analyst expectations

Price target increased by 8.1% to kr.123

Here's What's Concerning About Ambu's (CPH:AMBU B) Returns On Capital

Consensus EPS estimates increase by 14%

Second quarter 2024 earnings: EPS misses analyst expectations

Ambu A/S' (CPH:AMBU B) Subdued P/S Might Signal An Opportunity

Returns On Capital Signal Tricky Times Ahead For Ambu (CPH:AMBU B)

Results: Ambu A/S Exceeded Expectations And The Consensus Has Updated Its Estimates

First quarter 2024 earnings released

Ambu A/S Maintains Earnings Guidance for the Full-Year 2023/24

Price target increased by 10% to kr.101

Price target increased by 7.2% to kr.91.83

A Piece Of The Puzzle Missing From Ambu A/S' (CPH:AMBU B) Share Price

Ambu A/S Elects Shacey Petrovic as Vice Chair of Board of Directors

Ambu A/S Announces Henrik Ehlers Wulff Not to Run for Re-Election for Board of Directors

Ambu A/S Provides Earnings Guidance for the Full-Year 2023/24

Price target decreased by 9.0% to kr.87.00

Is Ambu A/S (CPH:AMBU B) Trading At A 42% Discount?

Ambu A/S Appoints Henrik Skak Bender as Member of the Executive Management, Effective 1 January 2024

Ambu A/S Announces Chief Financial Officer Changes

Ambu A/S to Report Q2, 2024 Results on May 14, 2024

Ambu (CPH:AMBU B) Will Want To Turn Around Its Return Trends

Ambu A/S Narrows Earnings Guidance for the Full-Year 2022/23

Third quarter 2023 earnings released

Does Ambu (CPH:AMBU B) Have A Healthy Balance Sheet?

Ambu A/S Raises Earnings Guidance for the Full-Year 2022/2023

Does This Valuation Of Ambu A/S (CPH:AMBU B) Imply Investors Are Overpaying?

Ambu A/S Raises Earnings Guidance for the Full-Year 2022/2023

New minor risk - Share price stability

Returns On Capital At Ambu (CPH:AMBU B) Paint A Concerning Picture

Ambu (CPH:AMBU B) Has A Somewhat Strained Balance Sheet

Second quarter 2023 earnings: Revenues in line with analyst expectations

Price target decreased by 8.7% to kr.95.50

Returns On Capital At Ambu (CPH:AMBU B) Paint A Concerning Picture

Consensus EPS estimates fall by 15%

Consensus EPS estimates increase by 14%

Price target increased by 16% to kr.96.80

First quarter 2023 earnings released: EPS: kr.0.09 (vs kr.0.08 in 1Q 2022)

Ambu A/S Provides Earnings Guidance for the Financial Year of 2022-2023

We Think Ambu (CPH:AMBU B) Is Taking Some Risk With Its Debt

Ambu (CPH:AMBU B) Will Be Hoping To Turn Its Returns On Capital Around

High number of new directors

Ambu A/S Provides Earnings Guidance for the Financial Year of 2022-2023

Full year 2022 earnings: Revenues in line with analyst expectations

Consensus forecasts updated

Ambu A/S to Report Q3, 2023 Results on Aug 31, 2023

Is Ambu A/S (CPH:AMBU B) Trading At A 30% Discount?

Ambu A/S(CPSE:AMBU B) dropped from FTSE All-World Index (USD)

Ambu (CPH:AMBU B) Will Want To Turn Around Its Return Trends

Now 20% undervalued after recent price drop

Price target decreased to kr.76.50

Third quarter 2022 earnings: Revenues in line with analyst expectations

Ambu A/S Reaffirms Earnings Guidance for the Full-Year 2021/2022

We Think Ambu (CPH:AMBU B) Is Taking Some Risk With Its Debt

Consensus forecasts updated

Ambu A/S Revises Earnings Guidance for the Full-Year 2021/2022